MEP16208A - A combination comprising combretastatin and anticancer agents - Google Patents

A combination comprising combretastatin and anticancer agents

Info

Publication number
MEP16208A
MEP16208A MEP-162/08A MEP16208A MEP16208A ME P16208 A MEP16208 A ME P16208A ME P16208 A MEP16208 A ME P16208A ME P16208 A MEP16208 A ME P16208A
Authority
ME
Montenegro
Prior art keywords
combretastatin
combination
anticancer agents
apidophyllotoxins
taxanes
Prior art date
Application number
MEP-162/08A
Other languages
Bosnian (bs)
English (en)
Croatian (hr)
Inventor
Marie-Christine Bissery
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of MEP16208A publication Critical patent/MEP16208A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
MEP-162/08A 2001-03-15 2002-03-15 A combination comprising combretastatin and anticancer agents MEP16208A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27562701P 2001-03-15 2001-03-15
YUP-713/03A RS50682B (sr) 2001-03-15 2002-03-15 Kombinacija kombrestatina i anti-kancer agensa
PCT/EP2002/006758 WO2004037258A1 (fr) 2001-03-15 2002-03-15 Combinaison comprenant de la combretastatine et des agents anticancereux

Publications (1)

Publication Number Publication Date
MEP16208A true MEP16208A (en) 2010-06-10

Family

ID=23053164

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-2008-162A ME00056B (me) 2001-03-15 2002-03-15 Kombinacija kombrestatina i anti-kancer agensa
MEP-162/08A MEP16208A (en) 2001-03-15 2002-03-15 A combination comprising combretastatin and anticancer agents

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MEP-2008-162A ME00056B (me) 2001-03-15 2002-03-15 Kombinacija kombrestatina i anti-kancer agensa

Country Status (38)

Country Link
US (4) US20020183266A1 (fr)
EP (1) EP1439839B8 (fr)
JP (1) JP4991107B2 (fr)
KR (1) KR100849610B1 (fr)
CN (2) CN1935134B (fr)
AR (1) AR032989A1 (fr)
AT (1) ATE433750T1 (fr)
AU (1) AU2002304574B2 (fr)
BR (1) BR0208017A (fr)
CA (2) CA2673449C (fr)
CY (1) CY1109364T1 (fr)
CZ (1) CZ302451B6 (fr)
DE (1) DE60232673D1 (fr)
DK (1) DK1439839T3 (fr)
EA (1) EA006316B1 (fr)
EC (1) ECSP034766A (fr)
ES (1) ES2327617T3 (fr)
HK (1) HK1067039A1 (fr)
HR (1) HRPK20030734B3 (fr)
HU (1) HU228510B1 (fr)
IL (2) IL157891A0 (fr)
MA (1) MA27000A1 (fr)
ME (2) ME00056B (fr)
MX (1) MXPA03007552A (fr)
NO (1) NO332661B1 (fr)
NZ (1) NZ527526A (fr)
PE (1) PE20020909A1 (fr)
PL (1) PL205728B1 (fr)
PT (1) PT1439839E (fr)
RS (1) RS50682B (fr)
SI (1) SI1439839T1 (fr)
SK (1) SK287908B6 (fr)
TN (1) TNSN03060A1 (fr)
TW (1) TWI306028B (fr)
UA (1) UA75127C2 (fr)
UY (1) UY27208A1 (fr)
WO (2) WO2002074229A2 (fr)
ZA (1) ZA200306789B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1068870B1 (fr) * 1998-04-03 2006-06-07 Ajinomoto Co., Inc. Agents antitumoraux
US20050209310A1 (en) * 2000-12-22 2005-09-22 Chaplin David J Methods for modulating tumor growth and metastasis
GB0410817D0 (en) * 2004-05-14 2004-06-16 Angiogene Pharm Ltd Vascular damaging therapy
CN100431606C (zh) * 2004-11-22 2008-11-12 山东蓝金生物工程有限公司 一种抗癌药物组合物
CN1319978C (zh) * 2005-04-06 2007-06-06 西南合成制药股份有限公司 康布瑞汀化合物的制备方法
FR2895258B1 (fr) * 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
US20080104512A1 (en) * 2006-10-31 2008-05-01 Motorola, Inc. Method and apparatus for providing realtime feedback in a voice dialog system
JP5302328B2 (ja) * 2007-11-21 2013-10-02 オキシジーン， インコーポレイテッド 造血性新生物を治療するための方法
US20090209496A1 (en) * 2008-02-15 2009-08-20 David Chaplin Methods and compositions for enhancing the efficacy of rtk inhibitors
FR2939665B1 (fr) * 2008-12-12 2011-10-07 Sanofi Aventis Combinaison antitumorale associant l'ave8062a et le docetaxel
FR2945210B1 (fr) 2009-05-07 2011-07-01 Sanofi Aventis Combinaison antitumorale comprenant l'ave8062 et le sorafenib
EP2397135A1 (fr) 2010-06-18 2011-12-21 Sanofi Combinaison antitumorale comprenant de l'ombrabuline, un dérivé de taxane et un dérivé de platine
AU2011266635A1 (en) 2010-06-18 2013-01-10 Sanofi An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
EP2481404A1 (fr) 2010-11-15 2012-08-01 Sanofi Combinaison antitumorale comprenant de l'ombrabuline, un dérivé de taxane et un dérivé de platine
EP2407161A1 (fr) 2010-07-13 2012-01-18 Sanofi Combinaison antitumorale comprenant de l'ombrabuline et du bevacizumab
FR2968557A1 (fr) 2010-12-09 2012-06-15 Sanofi Aventis Combinaison antitumorale comprenant un derive de la famille des combretastatines et le cetuximab
FR2978663A1 (fr) 2011-08-01 2013-02-08 Sanofi Sa Combinaison antitumorale comprenant l'ombrabuline et le cetuximab, associee a la radiotherapie
FR2978662A1 (fr) 2011-08-01 2013-02-08 Sanofi Sa Combinaison antitumorale comprenant l'ombrabuline et le cisplatine, associee a la radiotherapie
EP3337495A4 (fr) 2015-08-18 2019-04-10 Mateon Therapeutics, Inc. Utilisation de vda pour améliorer des thérapies d'immunomodulation contre des tumeurs
US9980953B2 (en) * 2016-09-26 2018-05-29 Chong Kun Dang Pharmaceutical Corp. Combined composition for preventing or treating cancer comprising a benzophenone thiazole derivatives as a VDA and topoisomerase inhibitor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2601676B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Procede de preparation du taxol et du desacetyl-10 taxol
US4996237A (en) 1987-01-06 1991-02-26 Arizona Board Of Regents Combretastatin A-4
MX9102128A (es) 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
US5430062A (en) 1992-05-21 1995-07-04 Research Corporation Technologies, Inc. Stilbene derivatives as anticancer agents
US5731353A (en) 1993-09-08 1998-03-24 Ajinomoto Co., Inc. Stilbene derivatives and pharmaceutical compositions containing them
TW325458B (en) 1993-09-08 1998-01-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions comprising the same for anti-cancer
US5561122A (en) 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
TW334418B (en) * 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
EP1068870B1 (fr) * 1998-04-03 2006-06-07 Ajinomoto Co., Inc. Agents antitumoraux
US6242770B1 (en) * 1998-08-31 2001-06-05 Gary Bela Bronner Diode connected to a magnetic tunnel junction and self aligned with a metallic conductor and method for forming the same
GB9903404D0 (en) * 1999-02-16 1999-04-07 Angiogene Pharm Ltd Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis
WO2000061142A1 (fr) * 1999-04-14 2000-10-19 Dana-Farber Cancer Institute, Inc. Procede et composition pour le traitement du cancer
US6465448B1 (en) * 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
US6448030B1 (en) * 2000-02-18 2002-09-10 University Of Nevada-Las Vegas Method for predicting the efficacy of anti-cancer drugs
CN1200712C (zh) * 2000-10-27 2005-05-11 阿文蒂斯药物股份有限公司 用于治疗癌症的含喜树碱和1,2－二苯乙烯衍生物的组合物
CA2432792C (fr) * 2000-12-22 2012-04-03 Bristol-Myers Squibb Company Procedes relatifs a la modulation de la croissance tumorale et de la metastase
US6466448B1 (en) * 2001-06-11 2002-10-15 Network Appliance, Inc. Riser board retaining and air ducting structure for printed circuit boards

Also Published As

Publication number Publication date
MXPA03007552A (es) 2004-10-15
AU2002304574A1 (en) 2004-05-13
NO20034022D0 (no) 2003-09-11
HUP0600233A2 (en) 2008-06-30
CN1547471A (zh) 2004-11-17
AR032989A1 (es) 2003-12-03
CY1109364T1 (el) 2014-07-02
CA2470484C (fr) 2009-10-13
HRP20030734A2 (en) 2005-06-30
UA75127C2 (en) 2006-03-15
EP1439839A1 (fr) 2004-07-28
PL205728B1 (pl) 2010-05-31
RS50682B (sr) 2010-06-30
BR0208017A (pt) 2004-12-07
MA27000A1 (fr) 2004-12-20
PL374406A1 (en) 2005-10-17
SK287908B6 (sk) 2012-03-02
ZA200306789B (en) 2005-02-23
US6933320B2 (en) 2005-08-23
IL157891A0 (en) 2004-03-28
ATE433750T1 (de) 2009-07-15
WO2002074229A2 (fr) 2002-09-26
WO2004037258A1 (fr) 2004-05-06
SI1439839T1 (sl) 2011-09-30
HK1067039A1 (en) 2005-04-01
US20030060429A1 (en) 2003-03-27
CN1935134A (zh) 2007-03-28
NO332661B1 (no) 2012-11-26
AU2002304574B2 (en) 2005-09-15
ME00056B (me) 2010-06-10
CZ302451B6 (cs) 2011-05-25
TWI306028B (en) 2009-02-11
NZ527526A (en) 2006-11-30
UY27208A1 (es) 2002-08-30
CN1290504C (zh) 2006-12-20
ECSP034766A (es) 2003-10-28
IL157891A (en) 2010-06-16
US20050075295A1 (en) 2005-04-07
EA006316B1 (ru) 2005-10-27
DK1439839T3 (da) 2009-10-05
HUP0600233A3 (en) 2010-03-29
CN1935134B (zh) 2010-12-15
CA2673449A1 (fr) 2004-05-06
JP2005522527A (ja) 2005-07-28
HU228510B1 (en) 2013-03-28
CZ20032476A3 (en) 2004-07-14
JP4991107B2 (ja) 2012-08-01
EP1439839B8 (fr) 2010-09-01
CA2470484A1 (fr) 2004-05-06
EA200301015A1 (ru) 2004-08-26
SK11552003A3 (sk) 2004-03-02
KR20040067866A (ko) 2004-07-30
PT1439839E (pt) 2009-09-03
PE20020909A1 (es) 2002-12-09
KR100849610B1 (ko) 2008-07-31
NO20034022L (no) 2003-09-11
EP1439839B1 (fr) 2009-06-17
CA2673449C (fr) 2011-10-18
HRPK20030734B3 (en) 2006-11-30
US20020183266A1 (en) 2002-12-05
ES2327617T3 (es) 2009-11-02
US20070149476A1 (en) 2007-06-28
YU71303A (sh) 2006-08-17
TNSN03060A1 (en) 2005-12-23
DE60232673D1 (de) 2009-07-30

Similar Documents

Publication Publication Date Title
MEP16208A (en) A combination comprising combretastatin and anticancer agents
CY1121314T1 (el) Παραγωγο ραπαμυκινης για την θεραπευτικη αντιμετωπιση του καρκινου του πνευμονα
ES2187519T3 (es) 7-halogeno-y 7beta,8beta-metano-taxoles, uso antineoplasico y composiciones farmaceuticas que los contienen.
CY1115289T1 (el) Μεθοδοι αγωγης εναντι ασθενειας που σχετιζεται με φλεγμονη
UY27943A1 (es) Composiciones y mctodos para tratar el crncer usando inmunoconjugados de anticuerpo para cd44 citotnxicos y agentes quimioterapcuticos
IS6658A (is) Ný efnasambönd
NZ514409A (en) C7 ester substituted taxanes as antitumor agents
ATE538124T1 (de) Imidazokondensierte tricyclische verbindungen auf thiazoloä4,5-büpyridin-basis und pharmazeutische zusammensetzungen damit
ES2123996T3 (es) Analogos de 7-etertaxol, uso antineoplasico y composiciones farmaceuticas que los contienen.
DE60001974D1 (de) Derivate von flavonen, xanthonen und kumarinen
ATE405568T1 (de) Cytotoxische mittel
WO2004098524A3 (fr) Complexes de platine a lipides et leurs procedes d'utilisation
YU21404A (sh) Supstituisana jedinjenja benzimidazola i njihova primena u lečenju raka
IL151198A0 (en) Tricyclic imidazopyridine derivatives and pharmaceutical compositions containing the same
WO2005054172A3 (fr) Composes derives de jasmonate, compositions pharmaceutiques et methodes d'utilisation associees
WO2005079471A3 (fr) Compose de cytotoxine et procede d'isolement
DE69917005D1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
WO2002078690A3 (fr) Agents anti-tumoraux taxoides et compositions pharmaceutiques basees sur ces derniers
EE200200681A (et) Akrüloüüldistamütsiini derivaati sisaldav farmatseutiline kompositsioon, derivaadi kasutamine tuumorivastase ravimi valmistamiseks ning kombineeritudravimpreparaat
BR0116123A (pt) Carbazóis antitumorais
DE60226313D1 (de) Verwendung von sesquiterpene enthaltenden zusammenstellungen zur behandlung von krebs
ATE298328T1 (de) Taxan-derivate für die behandlung von krebs
WO2002026730A3 (fr) Quinolones fluorees utilisees en tant qu'agents antimitotiques et antitumoraux
UY26498A1 (es) Pirroles sustituidos
AR022719A1 (es) Una composicion sinergica antitumoral.